Oxford experts: no strong evidence Oxevision improves safety
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Oxford University experts told the Lampard Inquiry that 45 studies used to justify NHS rollout of Oxevision did "not provide strong independent evidence of improved patient safety, acceptability or cost effectiveness," noting some involved the technology's own employees or were not extensive enough.
- The Lampard Inquiry is examining the deaths of more than 2,000 mental health patients in Essex over a 24-year period, with Baroness Lampard set to decide in October whether to make interim recommendations.
- LIO Health, which makes Oxevision, defended the infrared-sensor and camera system, saying it helped staff respond to 1,453 safety incidents over four years in a single trust and arguing randomised trials are difficult to run in mental health wards.
- Hodge Jones & Allen, representing more than 120 bereaved families, said the experts showed "no clear or meaningful evidence" that Oxevision improves patient safety or care.
- Stop Oxevision spokesperson Hat Porter said the findings raised concerns about broader NHS regulation, warning that "a technology without any kind of robust independent evidence base can just be rolled out" widely.
- Essex Partnership University NHS Foundation Trust, which uses the technology, said the inquiry's recommendations would be "an important part" of improving its care, while NHS England was contacted for comment.
Why it matters: With more than 120 bereaved families represented at the inquiry and Oxevision deployed across NHS mental health wards, the experts' finding that its justification rests on conflicted and underpowered research directly challenges a vendor defence built on real-world incident counts — giving the inquiry's October interim-decision window concrete ammunition on whether the technology should remain in use pending the 2028 final report.
